Hims House

Max Marchione discusses Superpower's peptide launch, pricing strategy, and critiques Hims' platform and recent performance

50 min Listen to the original Episode page
PeptidesHimsSuperpowerHealthcare TechGLP-1AI Drug DiscoveryCompetitive Strategy

Summary

Max Marchione details Superpower's launch of BPC-157 and CJC-1293, emphasizing transparent pricing and ecosystem retention over individual SKU loyalty. He predicts a significant drop in peptide prices by 2030 due to manufacturing efficiencies and contrasts Superpower's brand-focused model with Hims' performance marketing. Marchione also disclosed selling all Hims shares, citing a short-term valuation play rather than long-term conviction. Critics Jonathan Stern and Speaker 1 argue Hims suffers from technical debt, organizational bloat, and recent subscriber losses, while predicting AI will revolutionize drug discovery within a decade.

Key takeaways

  1. 1
    Hims reported its first-ever quarter-over-quarter subscriber loss and a gross margin decline to 57% in Q3, according to Jonathan Stern.

    Jonathan Stern · 41:12

Episode sections

  1. 1:50 – 3:16

    Peptides hype vs substance

    Max Marchione acknowledges the shift of peptides from esoteric to mainstream, driven by biological enhancement desires.

  2. 3:16 – 4:38

    Superpower peptide launch details

    Details on the launch of BPC-157 and CJC-1293 pre-orders, pricing, and product availability.

  3. 4:38 – 9:34

    Pre-order demographics and volume

    Analysis of new customer acquisition and volume drivers, primarily BPC-157.

  4. 9:34 – 13:07

    Retention strategy and ecosystem focus

    Contrast between Superpower's ecosystem retention and Hims' SKU-focused performance marketing.

  5. 13:07 – 18:12

    Pricing and margins outlook to 2030

    Predictions of price drops to $70/month by 2030 due to manufacturing efficiencies.

  6. 18:12 – 19:23

    Hims pricing and product strategy

    Critique of GLP-1 'gotcha' pricing and prediction that Hims will adopt similar transparent pricing.

  7. 19:23 – 22:56

    US vs China manufacturing and Hims facility

    Assessment of Hims' California facility as a marketing play and the superiority of Chinese API manufacturing.

  8. 22:56 – 30:20

    Oral vs Injectable BPC-157

    Distinction between oral use for gut health and injectable for systemic healing, and regulatory constraints on claims.

  9. 30:20 – 34:00

    Tech execution and organizational structure at Hims

    Critiques of Hims' legacy code, remote teams, and lack of a true health platform compared to competitors.

  10. 34:00 – 37:40

    Competitive advantages and organizational bloat

    Comparison of Hims' marketing DNA and bloat against Ro's focused, lower-headcount model.

  11. 37:40 – 39:42

    Hims strategic focus and international expansion

    Discussion on Hims' SKU expansion versus Ro's narrowing focus and implications for efficiency.

  12. 39:42 – 41:09

    Max Marchione's sale of Hims shares

    Confirmation of Marchione selling all Hims shares on Nov 3rd as a short-term valuation play.

  13. 41:09 – 45:11

    Hims Q3 performance and subscriber loss

    Jonathan Stern highlights Hims' first quarterly subscriber loss and margin decline to 57%.

  14. 45:11 – 50:09

    Peptide launch predictions for competitors

    Predictions that Hims and Ro will launch peptides, while Aura and Whoop will not.

Assets discussed

AssetKindStanceContext
OpenAIprivate companyneutralYour sense is that anthropic is ahead of OpenAI here?

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

HHS cleared the way for compounding pharmacies to make six peptides, including BPC-157 and TB-500, two weeks prior to the interview.

Jonathan Stern ·1:19

How to verify: Check HHS announcements or FDA enforcement discretion notices from October 2026 regarding compounded peptides. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Superpower launched peptide pre-orders two days after HHS clearance.

Unidentified speaker (UNKNOWN) ·1:38

How to verify: Check Superpower's website launch history or press releases from late October 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

BPC-157 is priced at $149 and CJC-1293 (CMAX) at $199 on Superpower.

Unidentified speaker (UNKNOWN) ·4:26

How to verify: Check Superpower's current product page for peptide pricing. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

BPC-157 accounts for the majority of Superpower's peptide pre-order volume.

Unidentified speaker (speaker_1) ·7:04

How to verify: Internal Superpower sales data; not publicly verifiable without company disclosure. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Superpower uses a co-licensed compounding pharmacy for final formulation and cold shipping.

Unidentified speaker (speaker_1) ·7:31

How to verify: Check Superpower's terms of service or pharmacy partner disclosures on their website. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

90% of Superpower members discover an out-of-range biomarker; 80% of those improve it between tests.

Unidentified speaker (speaker_1) ·12:32

How to verify: Superpower internal data; verify via company whitepapers or investor presentations if published. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Hims owns a peptide manufacturing facility called CS Bio in Menlo Park, California.

Jonathan Stern ·20:08

How to verify: Check Hims' SEC filings (10-K or 10-Q) for asset acquisitions or press releases regarding CS Bio. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Most major pharmaceutical APIs (e.g., Lilly) are manufactured in China or India.

Unidentified speaker (speaker_1) ·22:33

How to verify: Check pharmaceutical supply chain reports or company disclosures from Eli Lilly and Novartis regarding manufacturing locations. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Marchione believes BPC-157 prices will drop to $70/month by 2030 due to cost reductions and margin compression.

Unidentified speaker (speaker_1) ·16:28

How to verify: This is a forward-looking claim; verify by tracking peptide prices in 2026 against manufacturing cost trends. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Hims has not built a real tech platform or 'home for health' system, despite strong capital allocation.

Unidentified speaker (speaker_1) ·30:20

How to verify: Review Hims' (HIMS) SEC filings (10-K/10-Q) for R&D spending and product updates; compare app store ratings and engagement metrics against competitors like Aura and Whoop. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Hims' app receives a preponderance of one- and two-star reviews on the App Store due to bugs and poor AI experience.

Unidentified speaker (UNKNOWN) ·32:09

How to verify: Check the Apple App Store or Google Play Store for Hims' current user reviews and star ratings. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Mo El Shinawi was hired as CTO 18 months ago and Dirja Kaur 17 months ago, yet Hims has not shipped serious tech improvements.

Jonathan Stern ·32:28

How to verify: Check Hims' (HIMS) SEC filings for executive appointments and press releases for product launches during that period. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Hims is a remote and distributed team, which Speaker 1 claims hinders product innovation.

Unidentified speaker (speaker_1) ·33:11

How to verify: Review Hims' (HIMS) SEC filings for employee count and location disclosures; check company announcements regarding remote work policies. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Hims has approximately 2,400 employees as of December 31, 2025, excluding pharmacy/manufacturing, leaving ~1,000 corporate staff.

Jonathan Stern ·35:41

How to verify: Check Hims' (HIMS) Q4 2025 earnings release or 10-K filing for employee count and segment reporting. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Ro has roughly 400 employees and has not grown headcount in five years.

Jonathan Stern ·35:41

How to verify: Check Ro's (RO) SEC filings for employee count trends over the past five years. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Ro's domestic revenue surpassed Hims' domestic revenue.

Jonathan Stern ·36:11

How to verify: Compare Ro's (RO) and Hims' (HIMS) Q3/Q4 2026 earnings reports for domestic revenue figures. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Hims lost subscribers quarter-over-quarter in Q3, the first time in company history.

Jonathan Stern ·41:12

How to verify: Review Hims' (HIMS) Q3 2026 earnings release for subscriber count changes. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Hims' gross margins fell to 57% in Q3.

Jonathan Stern ·41:12

How to verify: Review Hims' (HIMS) Q3 2026 earnings release for gross margin percentage. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Speaker 1 sold all Hims shares on November 3rd.

Unidentified speaker (UNKNOWN) ·40:29

How to verify: Check Max Marchione's X (Twitter) posts from early November for confirmation of the sale date. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify Hims' Q3 2026 10-Q or earnings release for subscriber churn rates and gross margin figures.
  • Check Superpower's HHS clearance documentation for BPC-157 and CJC-1293 to confirm regulatory status.
  • Review Hims' app store ratings and recent user reviews to assess the 'buggy' claims made by critics.
  • Investigate the manufacturing capabilities of CS Bio in California versus Chinese API producers for cost and quality comparisons.
  • Confirm Max Marchione's Form 4 filing with the SEC to verify the date and volume of Hims share sales.
  • Search for clinical studies on oral vs. injectable BPC-157 efficacy to validate Superpower's product limitations.
  • Analyze Ro's headcount and operating expenses in their latest filings to evaluate the 'organizational bloat' claim.
  • Look for Dario Amodei's original statements on AI and disease cure timelines to contextualize the 10-year prediction.
Full transcriptexpand

0:00Unidentified speaker (UNKNOWN): Welcome

0:00Jonathan Stern: to Him's House. Today I'm talking to Max Marchioni, CEO of Superpower. And yes, this episode is brought to you by Superpower. I got a blood draw with them recently, 100 plus biomarkers. But honestly, the blood test was the least interesting part of the whole thing. After the blood test, I uploaded years of old labs, and now I can chat with an AI that knows my full medical history. I even put it up against ChatGPT. Superpower is way better. because it actually knows me. Superpower is also launching peptides soon. Join their wait list at superpower.com/slash peptides. And speaking of building in healthcare, people ask me all the time, what does it actually take to start a telehealth business? Usually I respond with three things. Number one, licensed doctors in all 50 fifty states. Number two, a pharmacy to fill prescriptions and number three, compliance that actually holds up. CareValidate does all of this for you so you can be live in as little as 30 days. Your brand, their infrastructure, go to carevalidate.com slash hymns house today to sign up. And now here is my conversation with Max Marchioni. Marcioni. Hymns House episode eighty-eight. My name is Jonathan Stern. I'm here today with Max Marcioni, co-founder and CEO of Superpower for what will

1:19be his third appearance on the show. Two weeks ago, HHS opened a path for compounding pharmacies to make six peptides, including BPC one five seven and TB five hundred. Two days later, Superpower launched its peptides offering and is now officially taking pre-orders. Very excited to dig into

1:38Unidentified speaker (UNKNOWN): it.

1:39Jonathan Stern: all of Max Marcioni, welcome back to him's house.

1:42Unidentified speaker (speaker_1): Jonathan, excited to be back, man. Um, I I love these conversations. So uh much, much to chat about.

1:50Jonathan Stern: You're on the show back in February. At that point, you said peptides would be the biggest consumer category of 2026. What did you get right and what did you get wrong?

2:01Unidentified speaker (speaker_1): Um, well, it's funny, right? Because in February, uh, people were not talking about peptides nearly the way they are today. Um, we forget how much has changed. I um first started taking peptides around August last year, which feels really, really recently. Back then, no one was talking about peptides, no one knew about them, they were very esoteric. Now, like there are peptide parties. There were like three peptide parties in the past couple of weeks, NASA. People are pending peptide onto the end of everything. So I think from a consumer perspective, it is one of the biggest, if not the biggest, uh uh kind of trends and themes. Um, I think it's still just getting started. I think right now there's hype without necessarily the substance, but I think that a lot of substance is going to come because peptides as a theme capture

2:49Unidentified speaker (UNKNOWN): things

2:50Unidentified speaker (speaker_1): that allow. people to enhance human biology, right? And it's a very primitive human desire to want to constantly evolve and improve and enhance oneselves. And the implication of AI plus this kind of Darwinistic imperative plus this direct consumer kind of empowerment of the individual in and health means that we're going to have many more enhancement therapeutics and peptides is is the catch-all for that theme.

3:15Unidentified speaker (speaker_2): Awesome.

3:16Jonathan Stern: Let's get into the superpower launch. What did you launch at what prices? And what can you say about how it's gone so far?

3:24Unidentified speaker (speaker_1): Our belief has always been that we want to be at the at the frontier, right? There's a gap between the kind of healthcare maybe Jeff Bezos gets and what most people have access to. Right? If you look at the kind of billionaire-level care, they have access to frontiers. frontier therapeutics. They have access to physicians with knowledge of peptides and things that can help someone through multiple stages of their health and life. Um, so that's always been our promise to our members. Let's empower the individual, let's give them access to things uh with physician support. Um, one of the first ways we've done that in the therapeutic side is what we did last uh last two Thursdays ago now. Um uh which was uh uh introduce the the the peptides the HHS has said um are going to be legal and can now be compounded without enforcement action. So superpower.com slash peptides now has a handful of them live. BPCE um one five seven, uh uh the the GLP1s, GLP ones, CMAX, C Macs, epitalon, etc.

4:25Jonathan Stern: Yep.

4:26Unidentified speaker (UNKNOWN): So

4:26Jonathan Stern: I'm seeing BPC one five seven and T B five hundred for a hundred forty nine dollars, Mod C for 199, um oral BPC as well, which is interesting. Um

4:39Unidentified speaker (UNKNOWN): what

4:39Jonathan Stern: percent is coming from existing superpower members versus new people?

4:43Unidentified speaker (speaker_1): Right now we're in pre order stage. So we'll start um uh going live soon, but most of the pre-orders pre orders are from new people. Okay.

4:51Unidentified speaker (UNKNOWN): The

4:51Unidentified speaker (speaker_1): thing that I found really surprising, I expected us to launch, I expected it to be mostly all the people already take peptides, saying I'm switching to superpower. And we have a few of them. I've had messages of people saying, I'm not going to my dodgy Chinese telegram dealer anymore, I'm going to superpower. But the thing I found really interesting is the number of people who have heard about peptides, who have not wanted to buy from an illegal grey gray market, and now are like oh wow, I feel finally feel like I can explore this area of medicine because I trust the brand, I trust the physicians behind it, I trust the fact that there's blood testing alongside it. Um so that that was what surprised me.

5:29Jonathan Stern: Got it. So most of the most of the pre-orders for Or a large people, a large amount of the people that you talk to are new to peptides, have not done peptides before.

5:39Unidentified speaker (UNKNOWN): and have been

5:39Jonathan Stern: waiting, have been waiting for this moment.

5:42Unidentified speaker (speaker_1): Yeah, correct. And um, I think there are many of them who who many more of them who who want to order but are still looking for a little bit more information, looking to understand. Like we have had dozens of questions to our concierge and support team saying, what peptide is is useful for what? Um uh it's it's really interesting because of how much uh um market awareness there is around the term peptide. I think it's somewhat established in people's minds that they can be useful. And the

6:10Unidentified speaker (UNKNOWN): next

6:10Unidentified speaker (speaker_1): step is people are trying to answer, can it be useful for me? Is this safe? Will the physician prescribe it, etc.?

6:18Jonathan Stern: Are there any numbers around pre-orders that you can disclose?

6:22Unidentified speaker (speaker_1): Uh no, no, we're we're not we're not sharing.

6:25Unidentified speaker (UNKNOWN): Are

6:25Jonathan Stern: you pleased though with the number that you've received?

6:28Unidentified speaker (speaker_1): Uh yeah, it's like it's like bigger than we expected. Yeah.

6:32Unidentified speaker (UNKNOWN): Oh

6:32Jonathan Stern: wow. Okay. And then in terms of like BPC 157 versus TB versus Mod C, what's the breakdown there? I imagine BPC is probably the most requested. Is that right?

6:44Unidentified speaker (speaker_1): Uh BPC157 BPC one five seven accounts for the majority of the volume there. Okay. Many people have wanted BPC. BBC one five seven and T B five hundred together. The HHS doesn't allow them in the same vial at the moment. Uh but we'll be introducing a bundle soon where you can uh at a single on a single kind of page have them both prescribed and and cold shipped to your door. But BPC accounts for um the the the vast majority of the volume.

7:09Jonathan Stern: That's right. Okay. So that's the Wolverine stack for the for those who are not aware, right? The usually sold in the same vial. Now you would like to be able to offer something like that. Will the clinician walk the subscribers through how to mix it? Will be will it be two injections? What are you anticipating there?

7:31Unidentified speaker (speaker_1): Yeah, so that there's no mixing. Mixing is this um phenomenon of of the gray market, right? We

7:36Unidentified speaker (UNKNOWN): have

7:37Unidentified speaker (speaker_1): a co license licensed compounding pharmacy that is making the final formulation and cold shipping it to your door. Um uh we'll have we'll have pens, there can be needles. Uh the physician will step someone through that, our kind of system will step someone through that. We'll have the videos that explain here's how you inject, Checked. here's how much to take, here's the dose that your physician has is prescribe. prescribed, But there's no reconstituting powder with water.

8:03Jonathan Stern: No mixing of cocktails.

8:06Unidentified speaker (UNKNOWN): No mixing

8:06Unidentified speaker (speaker_1): of cocktails, no getting your dose wrong. None of that. No.

8:11Jonathan Stern: Excellent. Which of the February peptides are you most excited

8:16Unidentified speaker (UNKNOWN): about?

8:17Unidentified speaker (speaker_1): Um, probably outside of BBC 157, probably epithalon. epitalon. Um, I

8:25Unidentified speaker (UNKNOWN): have

8:26Unidentified speaker (speaker_1): found epitalon. incredibly useful for sleep. I believe Andrew Human Huberman has said something similar. Um uh so probably epitalon.

8:35Jonathan Stern: What about G H K C U?

8:38Unidentified speaker (speaker_1): I don't think that's on the list of ones that is going to be um oh actually no that might be coming in February.

8:44Jonathan Stern: I believe that's a February

8:46Unidentified speaker (speaker_1): I think you might

8:46Unidentified speaker (UNKNOWN): be

8:46Unidentified speaker (speaker_1): right.

8:47Unidentified speaker (UNKNOWN): Yeah I

8:47Unidentified speaker (speaker_1): think you might be right. Um

8:50Unidentified speaker (UNKNOWN): I

8:50Unidentified speaker (speaker_1): think uh topical G so topical GHKCU is already legal. You can go to Amazon and you can buy topical GHKCU. Um injectable GHKCU, I do think, is going to be um one that many want to take for the impacts that uh uh folks quote for skin health.

9:09Jonathan Stern: I've heard it's mostly females that are interested at the moment.

9:13Unidentified speaker (UNKNOWN): Um

9:13Jonathan Stern: anything you can say. about your subscriber base? Is it like m half male, half female, mostly male, mostly female?

9:21Unidentified speaker (speaker_1): Pre-orders um mostly male. I think BPC157, the kind of target market is going to be the middle-aged man, especially, and then those looking to recover from injuries. Um G H KCU, I think, will skew primarily female.

9:35Jonathan Stern: Okay.

9:36Unidentified speaker (UNKNOWN): And

9:36Jonathan Stern: then I want to talk about retention. I've never done peptides, but from what I understand, BPC uh for injuries is often a short course. It's not something that you take month after month after month, which is different from GLP once, right? Which is a good business for HIMS and for others because it retains very well, or theoretically, it retains very well. You have to keep taking it for years and years and years. Um,

10:01Unidentified speaker (UNKNOWN): how

10:02Jonathan Stern: are you thinking about it? retention with these peptides, which are likely to be uh month after month after month, and then which are more one-off?

10:11Unidentified speaker (speaker_1): Yeah, we don't think about it as let's maximize retention on an individual skew. We think about it as let's make sure someone is on something when it can be helpful to them and not when it shouldn't be helpful to them. And the retention that matters is not retention on the individual skew. it's retention in the ecosystem, in the world of superpower. Right? Do people trust us and do they come back to us when they need something? Not all the time, but when they need something. Um, which is a change from the way marketing has been done. If you look at HIMS, it's rare that they're marketing the overall platform and and world and ability of the system to take care of you and be kind of the doctor in your pocket. They're rarely doing that. It's typically performance marketing for an individual SKU where you pay back your CAC primarily based on the number of months someone stays on your product. The implication is I think brand marketing starts to matter a little bit more. The relationship or trust someone has in the overall system matters a little bit more. The ability for the kind of health system to hold someone's hand across multiple stages of their journey matters a little bit more. So that's how we think about things. I don't think BBC 157 should be taken chronically the way people might take a GLP1 chronically. I think it's a as needed. This can be helpful if the doctor deems it suitable and prescribes it. But you don't always need

11:31Unidentified speaker (UNKNOWN): it.

11:32Jonathan Stern: So what is the number one way that you keep people on platform and as superpower members after? their BPC course ends? Is it the app? Is it the technology? Is it labs? Is it another skew?

11:47Unidentified speaker (speaker_1): Yeah, it's um primarily two things. It's um primarily um one having everything in one place, so actually being a home for health, such that when someone wants to access something, it's easy for them to do so. They don't have to go hunting around health gift. Healthcare feels easy, right? Like healthcare right now is I'm in the industry and it's still hard. So hard to get a prescription or a referral or a test. There's no one place where you can manage your health. So that's the first thing. Do we make it easy to manage your health? The second thing is: do we continuously generate insights for people? Right? Is is is the AI and is our medical team actually helping someone learn things about. their health such that they uh uh drive outcomes? Right. We see around 90% of our members discover a biomarker out of range when they're doing blood testing. And between tests, 80% of them improve it. Right. So they're learning something about their health. They're they're improving um their health. We have members who have come to us and said, I've been grappling with chronic fatigue for 20 years, and your AI helped me realize uh helped me connect the dots,

12:52right? It helped me have a look at all of my data, have it in one place, connect the dots and know what I should chat about with my doctor, with my uh physician. So it's like one, everything in one place, and then two, the ability to make sense of it, the intelligence.

13:07Jonathan Stern: Let's move to pricing. We don't have to dwell on this, but I I do want to get this in here. How are you thinking? about pricing across membership, medication, labs, and everything else that you offer?

13:21Unidentified speaker (speaker_1): We want to um uh price quite low. Um our goal is not maximize the margin on an individual SKU. It's have an ecosystem with affordable prices and really high quality at those prices, um, such that members want to come back. Now I don't I don't pretend we're gonna be the the cheapest. cheapest. If you want the cheapest, go to Telegram and buy powder from China, right? But if you want uh physician review plus lab testing plus US compounding plus cold shipping to your door, plus third party testing, plus the overall platform, um that that's where we sit. I think we're the by far the best option when you combine all of those things.

14:00Jonathan Stern: One thing I noticed that you guys are doing is bundling. in the labs with the medication. So that if you order BPC 157, you get labs for free. Do you expect others to bundle in labs as well?

14:13Unidentified speaker (speaker_1): I suspect so, yeah.

14:15Jonathan Stern: Okay.

14:16Unidentified speaker (UNKNOWN): Um

14:17Unidentified speaker (speaker_1): that said, um uh I think there's not a single company out there, not a single one that I think does a good job of interpreting lab results and creating a velvete velvety experience. around that, but besides what we've done. Like there are so many companies that say we do lab testing, and I've

14:32Unidentified speaker (UNKNOWN): tried

14:32Unidentified speaker (speaker_1): them all. It's just horrible. You send it's like the old-fashioned way of doing it where you get a shitty report back with no uh ability of the system and the app to actually make sense of the data.

14:42Jonathan Stern: What are the what are the three top I've heard you say this before, and I agree. I use the app. Um, I'm a superpower super power member. It is it is really well done, Max. And like you guys are sponsoring the show, and I do lead with that each each episode. But I like I have to say, I've used other apps, they're not as good. What what is it though about the labs offering, superpower labs offering, that you think is the real differentiator versus others?

15:12Unidentified speaker (speaker_1): Yeah, I think a big part of it is um once you have your data, two things, maybe three things. One is can you explore it? Can you just explore it and navigate it and read about your markers in a really delightful uh interface? I think the second thing, which is even more important, is what does it mean, right? How did your labs relate to your genome? How does that relate to your gut microbiome? How does that relate to your family health history? How does that relate to all of your past data, which we're automatically pulling in? So, what does it mean? How do we make sense of it? How do we connect the dots? Um, so that's probably the second thing. And the third thing is um, after you have your labs, is it easy to take action? And I think we've done an okay job of that today. I think we've done a better job than anyone else, but I think we've done an okay job today. What's coming in January for us is like this this step change in terms of the ability for this. the system to take action and and be your your partner on a health journey. And that just means it's not about lab testing. It's lab testing as the starting point on your kind

16:12of lifelong journey to health.

16:15Jonathan Stern: Final couple things on pricing. Let's fast forward to twenty thirty. What do you think a month of BPC one 157 five seven will cost?

16:24Unidentified speaker (speaker_1): I think pretty low. I think um prices will get down to 70 a month maybe and there'll be two drivers of that. One is the fundamental physics cost of um delivering the thing is going to be cheaper. Um compounding is going to be cheaper and more automated. API is going to be um uh cheaper because of new ways of of um actually creating the the the the peptide chain itself There will likely be efficiencies across like shipping and the and the supply chain there. There'll be efficiencies across the doctor ordering and all of that. So I think the physics cost goes down. And then I think margins compress a little bit as well. Let's say that kind of steady state market margin today is between 40 and 60%. percent. I think we're

17:11Unidentified speaker (UNKNOWN): actually

17:12Jonathan Stern: gross gross

17:13Unidentified speaker (UNKNOWN): margin.

17:14Unidentified speaker (speaker_1): Gross

17:14Unidentified speaker (UNKNOWN): margin.

17:15Unidentified speaker (speaker_1): I think we'll see that compressed to maybe for 30 to 50%. And uh that means we get a 20% reduction in the physics cost and maybe a 20% reduction in the margin, and the the price comes down accordingly.

17:29Jonathan Stern: More or less peptide vendors in five years.

17:34Unidentified speaker (speaker_1): Oh um probably more by number, but the they'll the the I don't I think the market will be quite concentrated. I

17:41Unidentified speaker (UNKNOWN): think the

17:41Unidentified speaker (speaker_1): majority of people will go to a small number of platforms that are a really good job at trust, quality, pricing, the experience around the peptide, etc.

17:53Unidentified speaker (UNKNOWN): And

17:53Jonathan Stern: moving to HIMS, uh, they've announced that they'll be launching some or more ling Lin glutathione, Glutathion, NAD, plus, and then BPC 157 and T. TB500 once allowed. So we have no idea. I mean, there's technically allowed now, although we don't know when hymns is going to launch.

18:12Unidentified speaker (UNKNOWN): At

18:12Jonathan Stern: least with BPC and TB, how do you think HIMS will price those? You guys are 149. Where will HIMS be?

18:20Unidentified speaker (speaker_1): I suspect they're gonna be very similar. There might be 10 ten less or 10 ten more or the exact same, but I suspect that. they'll be very similar.

18:30Unidentified speaker (UNKNOWN): And

18:30Jonathan Stern: do you think there will be a membership there? Like thirty nine a month, forty nine a month, which would bring the all in cost to two hundred.

18:38Unidentified speaker (speaker_1): Maybe it's hard to say. Oh there's there's a chance him that him says the first month's really low price, and then the like the gotcha, we're increasing the next month. There's a chance we see companies do that.

18:50Unidentified speaker (UNKNOWN): Yeah.

18:50Jonathan Stern: the gotcha.

18:52Unidentified speaker (UNKNOWN): Yeah,

18:52Unidentified speaker (speaker_1): like GLP1s, right? Like our GLP one offering today is 79 a month every month, right? You need to have a super power membership as well. That's that's testing. Um 79 a month every month, where it's like clear, it's like transparent. If you look at most GLP1 companies, it's 60 bucks the first month, then 150, right? Rather, There are all of these like are gotchas. So I really believe. uh at least the approach we're taking is simple, clear, same every month. Let's just make it transparent, etc.

19:23Jonathan Stern: Where do your active ingredients come from?

19:26Unidentified speaker (speaker_1): Um active ingredients come from all over. There are US uh uh uh manufacturing groups we work with, there or are at Chinese manufacturing groups. All that matters with active ingredient is what is the highest quality API at the lowest price? Right. It's kind of like if you look at your meds you might get from uh Ela Lilly or Novartis or any of those companies, most of it is manufactured in China. If you look at your iPhone, it's manufactured in China. And it's done in FDA registered facilities. It's done to a higher quality than they would be able to do onshore because. they've been doing this at scale for multiple decades.

20:07Unidentified speaker (UNKNOWN): Well,

20:08Jonathan Stern: and I have to ask you, Max, because HIMS owns this peptide manufacturing facility in California. Andrew said on the most recent call, we will be manufacturing the raw API in Menlo Park, California.

20:21Unidentified speaker (UNKNOWN): Do

20:22Jonathan Stern: you see that as overrated? Do you see that as the wrong choice? Would it

20:25Unidentified speaker (UNKNOWN): be better to get this?

20:33Unidentified speaker (speaker_1): Right? Classically, um

20:35Unidentified speaker (UNKNOWN): the

20:35Unidentified speaker (speaker_1): US has done a very bad job of manufacturing raw ingredients at a high quality and low price. Him's facility might be different. I know I know the guy they bought that from, and he's really talented, but I think it's primarily a marketing play rather than rather than anything else, right?

20:52Jonathan Stern: So quality and price. Um, do you think HIMS will be do you think it I think the facility is called CS Bio? Do you expect CS Bio to be competitive at either quality or price?

21:04Unidentified speaker (speaker_1): I don't know. Um, probably not, but because HIMS has removed an intermediary and owns the full stack, their margin will be roughly the same, right? They're They they're their their gross margin. Oh, see their operating margin is a little bit less because they have to operate the actual facility. Um uh but I I haven't seen the US do a great job of uh like fundamental unit manufacturing anywhere. It's like a pretty known thing. The US is It's not fantastic at manufacturing. Right.

21:35Unidentified speaker (UNKNOWN): No,

21:35Jonathan Stern: like you're you're not the first who's come on the podcast and said

21:39Unidentified speaker (UNKNOWN): like,

21:40Jonathan Stern: there are a few API manufacturers domestically, they're more expensive and they're not as good as what's coming out of China. The quality bar is not as high.

21:51Unidentified speaker (speaker_1): Yeah, like look, there's I think China uh often deserves a bad rep because people buy dodgy shit from non FDA registered facilities that are not inspected by the FDA, that are not made do not by meet a bunch of requirements. So as a result, like that deserves to be scrutinized. At the same time, the vast majority of the medications that people are buying are manufactured in FDA registered facilities in China that have quality standards above and beyond what like the Chinese are very, very, very meticulous, right? They're very good at manufacturing. The iPhone is a pretty good device. Um

22:29Unidentified speaker (UNKNOWN): Lily,

22:29Jonathan Stern: Lily, Lily's API. Where's that? Where's that coming

22:32Unidentified speaker (UNKNOWN): from?

22:33Unidentified speaker (speaker_1): I think it's mostly China and India. I could be wrong though.

22:36Jonathan Stern: Yeah. Yeah, we'll see. Um, I'm optimistic that this manufacturing facility in the US gives him some sort of edge, but to your point, maybe it's just marketing, or maybe the administration is happy. that it's coming out of the US. I have no idea. We'll

22:53Unidentified speaker (UNKNOWN): see.

22:55Jonathan Stern: Um walk us through your decision to launch oral BPC. How does that compare to the injectable form?

23:03Unidentified speaker (speaker_1): Um, yeah, we can't we can't mark make marketing claims around it until there are RCTs or clinical studies. The thing that I've seen, um, anecdotally, and the way I've seen physicians prescribe. is oral BPC for gut health, um, uh for gut lining, um, for gut problems, and injectable BPC for systemic healing, for injuries, for um kind of ligament and and tissue repair. Um, so I've seen physicians recommend different ones for different use cases.

23:37Jonathan Stern: Have you done both oral and injectable?

23:39Unidentified speaker (UNKNOWN): Uh

23:40Unidentified speaker (speaker_1): only injectable.

23:41Jonathan Stern: Got it. Okay, let's go back to marketing. Um, what sort of marketing are you allowed to do on peptides right now? Are superpower ads live and what do they look like?

23:52Unidentified speaker (speaker_1): Yeah, we have ads live. Um, we can't make claims around benefit, right? So we can't say take BPC to heal your bad elbow. Can't say that. Um, right. We cannot make claims around benefit. As a result, most of the marketing is um is uh BPC is now live. Right. So it's it's just the the name of the compound, it's a statement around it being live. Um it requires someone to have as a result some level of knowledge or to at least want to explore and then learn about it, search around the internet to learn about it. Um, I think the reality is peptides are very mimetic and a lot of people talk about them and a lot of people talk about the benefits independent of us, right? And as a result, um the actual compound itself um sells without us needing to make certain marketing claims.

24:44Jonathan Stern: What has to happen before you're able to make those claims?

24:48Unidentified speaker (speaker_1): Yeah, clinical studies. Um so where we're where are we're um we're uh kicking off one study at the moment um for uh uh this novel formulation that we've we've created. I can't share too much about it. And in the

25:01Unidentified speaker (UNKNOWN): new

25:01Unidentified speaker (speaker_1): year, we'll be starting some other studies as well.

25:04Jonathan Stern: Okay, so you are going, are those going to be with superpower customers, or are you guys doing this in the background on your own dime?

25:12Unidentified speaker (speaker_1): Um but but both. So some some of them are with superpower. customers, and then we're working with um certain like uh uh research organizations that are that are helping us also enrol other participants.

25:24Jonathan Stern: Once you have the results and the data, you can then make the claims on meta ads. Is that correct?

25:31Unidentified speaker (speaker_1): Um I think it depends on on the nature of the results and the nature of the data. I I we

25:36Unidentified speaker (UNKNOWN): should have

25:36Unidentified speaker (speaker_1): to give you a better answer, but that's that's one for that's the what one for the lawyers. And I'm

25:40Unidentified speaker (UNKNOWN): just

25:40Jonathan Stern: yeah, I'm just thinking through like will other companies cite superpowered data at that point? Would you allow that? Like could you

25:49Unidentified speaker (speaker_1): Yeah no

25:50Unidentified speaker (UNKNOWN): I I

25:50Unidentified speaker (speaker_1): I I if we publish a study I'll others can refer to that as well.

25:54Jonathan Stern: Others could could refer to that.

25:55Unidentified speaker (UNKNOWN): Okay.

25:56Jonathan Stern: Let's let's move to HIMS. HIMS just reported Q Q3. three

26:01Unidentified speaker (UNKNOWN): the

26:02Jonathan Stern: stock is down massively. Hymns announced that they will be launching peptides. The launch has not happened yet. Supposedly at some point in November, HIMS will launch some more linglutathione, B twelve, NAD plus, and L carnitine. BPC one five seven and TB five hundred will follow later. Um

26:22Unidentified speaker (UNKNOWN): I

26:23Jonathan Stern: I kind of want to get into Q3 at some point, but to start. why do you think him started with just BPC and TB500? Why not everything that you guys are launching?

26:36Unidentified speaker (UNKNOWN): Um,

26:36Unidentified speaker (speaker_1): they're they're doing a similar set of things. I just think hims is their thesis is somewhat different to ours, right? Like ours is we want to have a brand that stands for optimal health and that people go to when they want high high-quality, quality. trusted health at an affordable price. Um, and you come to us, you enter the superpower world, right? Because you know that it's an easy way to access things at the frontier. That's that's kind of our our approach, that's our brand ethos. Hims is let's launch a SKU and go really hard at performance marketing for that SKU. Let's build a mini pod whose job is just that SKU. skew. That means if you launch dozens of SKUs, well, you'd need dozens of pods, and that's very hard from a focus perspective. So we just take slightly different approaches to our philosophy on marketing.

27:25Unidentified speaker (UNKNOWN): Do you

27:25Jonathan Stern: expect TIMS will eventually launch Mots C, C Macs, some of the other stuff that you guys offer?

27:31Unidentified speaker (speaker_1): Yep.

27:32Jonathan Stern: Okay. And earlier this year, when we chatted, you said you don't really see superpowers. competing with HIMS. I from my perspective, um, Superpower is not HIMS's closest competitor, right? That's probably Roe or Nume or Life MD. Those companies I think are closer. But but with the launch of peptides, potentially even with the launch of labs, I think superpower is closing in on what HIMS offers and could properly be seen as something like a competitor. Do you feel that way as well?

28:10Unidentified speaker (UNKNOWN): I

28:10Unidentified speaker (speaker_1): think we go after somewhat different customers today. Um and I think our um overall philosophy at Superpower, the thing that matters the most is have we democratized high high-end end concierge medicine and brought that to everyone at an accessible price? Are we a home for health, right? Are people coming to superpower to manage their health? That's the thing that matters the most to us. Now, the way we get somebody into the ecosystem used to be more distinct from HIMS. It used to be very focused just on the diagnostics as an entry point into our world. Um, now we have uh therapeutic products as well as an entry point into our world. And HIMS is the same therapeutic products. So one could say we we we compete. And then at the same time, um, I'm just such a big but like I have seen so many people's lives change as a result of having access to high-quality medicine at the frontier that many doctors don't yet know about, right? And I think that we're still so early in this in this kind of theme and market and and trend. We end up getting to a world where where most people um

29:15want a better way to take care of their health. And uh as a result, yeah, maybe we compete. And at the same time, I think it's so early for both of

29:22Unidentified speaker (UNKNOWN): us.

29:23Jonathan Stern: It feels like Andrew has that exact same vision,

29:27Unidentified speaker (speaker_2): Max.

29:27Jonathan Stern: He's talked about concierge medicine. If you refer back to the Super Bowl ad, I think the tagline was the health gap is the wealth gap or or the wealth the wealth gap is a health gap, something like that. I I don't remember which was first. And so they definitely want to build a something like you've just described, and they want to democratize access to frontier medicine.

29:54Unidentified speaker (speaker_1): Yeah, I think to do that, um, you need to build really, really good technology. Um, and I I have a lot of respect. for him. They they are fantastic marketers. I think um Andrew has been fast sighted in terms of like vertically integrating. He's struck, I think, a pretty good balance of of like when to focus and do one thing and when to move to the incremental. They're very good at media buying. They're very good at capital allocation. They're very good at the numbers. And then at the same time, they have not built any real tech, right? They have not built a platform that one could say is is like your home for health. They're not close to having done that. Um I think that the the the vision's like like like it's it's it's very pretty consensus now, right? It's pretty established that there are going to be one, two, maybe a handful of companies that They become health systems in front of the current health system. That's inevitable. It's absolutely inevitable. Yep.

30:50Unidentified speaker (UNKNOWN): Um

30:51Unidentified speaker (speaker_1): the question is, what's the critical path there? Who who can actually prove that that they've done the things required to have that relationship with a customer? As far as I can tell, and tell me if you think I'm wrong, as far as I can tell, we're the only company on earth that is somewhat well, I don't think we're near there yet, but that has like somewhat gotten there. Um uh and I think that's partially because of the quality of the AI and the intelligence, it's partially because of the nature of our brand, which is like cool and people want to be part of it. People want to wear our merch and talk about it and tell their friends. And then

31:22Unidentified speaker (UNKNOWN): I

31:22Unidentified speaker (speaker_1): think it's partially because

31:23Unidentified speaker (UNKNOWN): um

31:24Unidentified speaker (speaker_1): we do a very good job of taking the initial interaction and then having someone engage with the rest of our ecosystem, right? Use us for more than just a single thing.

31:33Jonathan Stern: I think you guys are doing an incredible job. And I think there are a couple other companies doing an incredible job on tech too. Aura and Whoop come to mind.

31:43Unidentified speaker (UNKNOWN): It

31:43Jonathan Stern: at minimum, people visit, people use those apps every day and love the apps and like have this relationship with their sleep scores and talk about it with friends. And you can see that sort of product experience becoming something much, much bigger. With HIMS, people don't use the app every day. When they do use the app, they complain about bugs. I've said this on recent podcasts,

32:09Unidentified speaker (UNKNOWN): and

32:09Jonathan Stern: it's concerning and frustrating as a shareholder that they've rolled out this AI experience. If you go to the App Store and you look at recent reviews, a preponderance of the new reviews are one in two stars, customers that are not happy with the AI experience. 18 months ago. Mo El Shinawi was hired to be CTO. Dirja Kaur was hired, I think 17 months ago. And in that time, you have not seen the company ship serious tech, AI, or product improvements. My question to you is like something like a competitor: is what do you think is going on there?

32:51Unidentified speaker (speaker_1): When you have a legacy system that is not structured for the way code is written today, which is increasingly with AI and agents, is a really, really, really hard to ship things. Problem one. Problem two is many good marketing teams are remote and distributed. Um, and HIMS is a remote and distributed team. I'm yet to meet a single great product team that is remote and distributed. right? Like our whole product team isn't behind me in the office in SF, right? I'm gonna walk out of the meeting room after and everyone's there sharing ideas, talking. Problem three is like bloat. Um, uh, one of the companies that uh tries to compete with us is building an AI, and they have apparently a 30 person team. And if you chat with their at their AI, uh it hardly

33:36Unidentified speaker (UNKNOWN): 30 person

33:37Jonathan Stern: 30, sorry, 30 people

33:38Unidentified speaker (UNKNOWN): talking. total.

33:39Unidentified speaker (speaker_1): People just just in the AI chat, right? Oh

33:43Unidentified speaker (UNKNOWN): wow.

33:43Unidentified speaker (speaker_1): Uh they're their overall

33:44Unidentified speaker (UNKNOWN): company.

33:44Jonathan Stern: 30 people on their Enge team?

33:46Unidentified speaker (UNKNOWN): No,

33:47Unidentified speaker (speaker_1): no, no. Their whole Eng team's far bigger. But just in the AI part of what they do, they've got

33:51Unidentified speaker (UNKNOWN): a

33:51Unidentified speaker (speaker_1): 30 person team. We have like three geniuses, like teal fellows, people who raise $100 million to their past company, who's it's their baby. This is what they obsess over. They like go to bed at night thinking of this. We uh our head of engineering wakes up at 3 a.m. with an idea for how to improve the product and sends it to the channel. So I think like culturally, it's just hard for companies that do not have the DNA of building product and technology to do that. Um, and I think all of these companies started with slightly different DNA. Um, aura really started with like hardware DNA, him's really. started with marketing DNA. We really started with like product, software, AI, DNA. And it's not like one is good or bad. There are like multiple critical paths. And the reality is whomever creates the best experience of the user is going to be someone who does all of these things really well. You know, you need to. You need to do tech well, you need to do marketing well, you need to do science well.

34:46Jonathan Stern: I'm certainly concerned about the fact that HIMS is remote first. I couldn't agree more that I have not seen an engineering team that is world class where people are distributed across the country or the world. Uh I was a former software engineer and I was in office every day of the week. And that was fundamental to the success of the team. Couldn't have happened otherwise. I imagine something is true at something like that is true at HIMS because they have just announced, well, last quarter. plans to open up an in-person office for the engineering team. So that seems like a step in the right direction there. I think they're

35:22Unidentified speaker (UNKNOWN): I

35:23Jonathan Stern: don't know if it's going to be mandatory. I don't know that it's five days a week. We have no idea as investors. Maybe they'll announce, maybe not, but they are opening up a an RD. They're calling it an R RD and D site in Menlo Park. So okay, that's a step in the right direction. Um you mentioned bloat, Max. Yesterday we got some numbers from Roe. Roe hasn't really grown its employee count in five years. They're at roughly 400 hymns. Is it 2400 as of December 31st, 2025? Now, if you exclude international

36:01Unidentified speaker (UNKNOWN): and

36:02Jonathan Stern: you exclude the pharmacy and manufacturing folks at HIMS, maybe you're at a thousand. But it's still two to three times bigger than Roe, I have to think. And by the way, Roe's domestic revenue just surpassed HIMS. Do you think that there's a bloat problem?

36:22Unidentified speaker (speaker_1): Um, I think nearly every company has a bloat problem, right? So and Elon's the the classic example of this. The fact that you

36:30Unidentified speaker (UNKNOWN): can get 80%

36:31Unidentified speaker (speaker_1): to it to it. Um now uh the the the road thing is interesting because uh again, a lot of respect for road, they've been very focused. Um we can't just look at revenue without understanding the cost of that revenue. So it's it's really hard to understand these things in in isolation. That said, when you have less op OPEX, ed. you have less headcount. Um, guess what? All of a sudden you can justify higher CACs because your overall cash position could still be better. So I think there's a good chance that Roe pays more on customer acquisition, um, but that uh they just have lower all-in costs because they have less uh uh headcount. head count. Um all that's to say that yeah, the HIMS probably has a blow. bloke problem

37:15Unidentified speaker (UNKNOWN): and

37:15Unidentified speaker (speaker_1): a as does nearly every company.

37:17Jonathan Stern: Yeah. Did you see the note that Z posted yesterday?

37:21Unidentified speaker (speaker_1): It was really good. Uh it was really, really good. There are very few things that I read that I want to send to like the whole team, and I send that to the whole team. I'm like, I think we do like seventy 70% percent of this really well, and here are maybe a couple areas that like Z is on point and and we'll we we have to be better.

37:40Jonathan Stern: What most stood out from the from the article?

37:45Unidentified speaker (speaker_1): Focus.

37:46Unidentified speaker (UNKNOWN): Like

37:47Unidentified speaker (speaker_1): Z has just been so focused. There's a time when uh HIMS did a very small number of things, like did pills on the internet, and Roe did dozens of they started expanding into more and more SKUs. And now we've seen the inversion of that, where Roe rotors does are a very small number of things. They mostly focus on GLP ones. And HIMS has added more and more and more things. And it's funny how um uh we've seen this inversion of focus and potentially inversion of performance uh as as a result. And all that's to say that maybe this focus thing that everyone talks about actually has legs.

38:21Jonathan Stern: If HIMS could go back

38:24Unidentified speaker (UNKNOWN): a

38:24Jonathan Stern: year, a year and a half, Andrew could go back. a year and a half, do you think he would push for inter international like he did?

38:34Unidentified speaker (speaker_1): Well, probably. Like the re the reality is HIMS has three ways to grow. One is you double down on existing products and you acquire more members for that. Two is you introduce new products, um, which HIMS has done, or three is you introduce new markets and um HIMS has him hims has done that. So I I think he'd still um do the the international um still do the international thing but I I could be wrong.

38:57Jonathan Stern: In terms of focus then where do you think hymns could be more focused?

39:03Unidentified speaker (speaker_1): Um it depends on the strategic bets they want to take. Like if they want to win as In a D to C company, there's an argument that they should narrow skew SKU count to the ones that bring in the most revenue. and get really good at optimizing every part of that stack. If they want to win as a home for health, there's an argument that they should still narrow skew count and D to C, be like almost a little bit more profitability obsessed with the kind of classic direct-to-consumer Promotions motions, such that they can invest more resourcing, more time, more energy into building out the tech, into building out the platform. Um, yeah.

39:42Jonathan Stern: In early March, you tweeted that you finally bought some shares of HIMS. Do you still own those shares?

39:48Unidentified speaker (speaker_1): I sold them last Monday or Tuesday at around 1 p.m. Let me see my calendar. When was it? It was X.

39:56Unidentified speaker (UNKNOWN): You wrote

39:56Jonathan Stern: on your calendar

39:57Unidentified speaker (UNKNOWN): when

39:57Jonathan Stern: you sold when you sold?

39:59Unidentified speaker (speaker_1): No, no, but you you and I spoke on on Tuesday. and I I told you um I told you that I sold them earlier that day. So I was checking if we speak on Tuesday or Monday. Um so I

40:10Unidentified speaker (UNKNOWN): sold

40:11Unidentified speaker (speaker_1): all of my shares earlier that day.

40:12Jonathan Stern: Yeah, okay. So you sold prior to speaking with me. Why did you

40:16Unidentified speaker (UNKNOWN): I

40:16Unidentified speaker (speaker_1): I sold earlier in the day without even thinking about the fact I was speaking to you. And then uh uh the the there was there was a funny coincidence that uh uh stuck in my mind and and we we can recount now. And and

40:29Unidentified speaker (UNKNOWN): I

40:29Unidentified speaker (speaker_1): don't know, people for people who are wondering the date, that was the 3rd of November um uh when I sold.

40:35Jonathan Stern: Sold on November 3. Okay. So the share price was

40:43Unidentified speaker (UNKNOWN): Oh

40:44Jonathan Stern: wow, okay. So mid-20, 20 like above 25, probably. Well,

40:48Unidentified speaker (UNKNOWN): as

40:49Jonathan Stern: we're recording this, share prices took $20. Did you see? So, like, congrats on avoiding that. Um, did you see the Q3 call, Max?

41:01Unidentified speaker (speaker_1): I didn't, I didn't see it. No, I saw the summary of it. Um, and some people on our team um

41:06Unidentified speaker (UNKNOWN): I'd say

41:08Unidentified speaker (speaker_1): notes

41:08Unidentified speaker (UNKNOWN): too.

41:09Jonathan Stern: I'd say the highlights were, at least from my standpoint, are that Him's lost subscribers quarter over quarter, first time in company history that that happened. And gross margins fell again to 57%. I'm less concerned about that. I would like to see them get back to 60 or 70%, but the cash matter, the cash in absolute terms, matters more to me than margin percentage. So uh the main concern. is that they're now losing subscribers and probably expect to lose subscribers again in Q4.

41:47Unidentified speaker (speaker_1): Mm-hmm. Um yeah, I think if you if you uh uh are home for health, you should see that subscriber number go up. You shouldn't necessarily see Really your margins go up. You might actually expect gross margin to go down. Um, but you'd want to see your retention improving, you'd want to see subscriber count going up.

42:06Jonathan Stern: Yeah.

42:07Unidentified speaker (UNKNOWN): Yeah, that was

42:08Unidentified speaker (speaker_2): a white hand

42:09Unidentified speaker (speaker_1): sold. I I didn't predict what was happening uh this week and last. Um I just had uh when I bought when it was really cheap earlier this year because I thought that they they should not be that cheap, and that was transitory. And that was my thesis. I just wanted to play the cheap too expensive, and and um that that. was my thesis. I I've never had like a long-term thesis per se around himself's ability to be the like health system in front of the health system. Maybe they can. I don't know. Um, but my thesis played out in there for us old.

42:40Jonathan Stern: Great. How is superpower doing overall? Is a new round coming soon? And what is on the roadmap?

42:49Unidentified speaker (UNKNOWN): Yeah,

42:50Unidentified speaker (speaker_1): we're we're we're stealthy about talking about new rounds and fundraising. Um but uh I can say that um in January or February next year we have some really big announcements coming. Um and uh we're doing really well. The past um we we like launched what, To August last year. We've done really, really well um since since then. Our members love us. Um, we have so many moving stories of ways we have impacted people's lives. We have someone who discovered stage one cancer recently through our tests. We have another person who who woke up and the AI told them to go to the ER and they were having a stroke. Um, and we literally probably saved save that person's life. Um, so just like dozens and dozens of heartwarming stories from our members, and that and that's why we're

43:39Unidentified speaker (UNKNOWN): here.

43:41Jonathan Stern: How are VCs thinking about the category right now in terms of home for health? And what can you say about the competition? Again, we have as I see it, the landscape mostly consists of superpower, function, hymns, Hims, row, aura, whoop.

44:01Unidentified speaker (speaker_1): I think it's

44:01Unidentified speaker (UNKNOWN): now consensus.

44:03Unidentified speaker (speaker_1): Yeah, I think it's now consensus that um this is a category and there will be a winner. I don't think it's necessarily consensus on who that winner will be. And I think these three different categories of companies um all have different advantages, right? Um HIMS's advantage is they have gross profit from an existing D2C The engine. Aura's or as advantage advantages, is they have um customers checking the app multiple times a day. Our advantage is that we have the best product and engineering team and and such a great relationship with our members. And in many respects, it's just like who can make a small number of decisions that puts one on the critical path to being the health system in front of the health system. And um uh for for all, like I don't I don't really mind who does it, I'm agnostic. All I care is that someone actually builds a better health system. That's that's the important thing. Um and uh I think we're we're we're we have to see how this plays out. Like some people might say it's the classic um uh it's a race for the incumbent to get innovation before the the new company gets distribution and I think we we definitely see that here.

45:11Jonathan Stern: Which of those six will launch peptides?

45:14Unidentified speaker (UNKNOWN): You

45:14Jonathan Stern: guys certainly will. Him certainly will. Will function row, aura, and whoop.

45:21Unidentified speaker (UNKNOWN): Uh,

45:21Unidentified speaker (speaker_1): I think hims

45:22Unidentified speaker (UNKNOWN): will.

45:22Unidentified speaker (speaker_1): I think row will. I don't think the others will.

45:25Unidentified speaker (UNKNOWN): You

45:25Jonathan Stern: think row will? Hmm.

45:28Unidentified speaker (speaker_1): Eventually. No, like Roe's vision is not to be the GLP1 company forever. They simply believe that that focusing on that earns them the right to do this. the next thing. But there comes a point in time when they need to do the next thing.

45:44Jonathan Stern: Jeff Tang came on the podcast and said he did not expect Ro to launch, but

45:50Unidentified speaker (UNKNOWN): maybe

45:50Jonathan Stern: they just

45:51Unidentified speaker (UNKNOWN): depends on

45:51Unidentified speaker (speaker_1): your timeline, right? Like, do

45:52Unidentified speaker (UNKNOWN): I

45:53Unidentified speaker (speaker_1): expect Ro to launch

45:53Unidentified speaker (UNKNOWN): in

45:53Unidentified speaker (speaker_1): the next 12 months? No. Do I expect Ro to launch in the limit? Almost definitely.

45:58Jonathan Stern: Before we go,

46:00Unidentified speaker (UNKNOWN): I

46:01Jonathan Stern: do kind of want to hear your thoughts on. what's going on in AI, drug discovery at anthropic and OpenAI. I I don't really have a healthcare background, so it's like difficult for me to really make sense of all of this. But some of the blog posts seem earth shattering. How are you thinking about what's going on at the Frontier Labs?

46:24Unidentified speaker (UNKNOWN): We

46:25Unidentified speaker (speaker_1): can think of drug discovery and maybe. in maybe two buckets, or drug development and discovery in two buckets. There's discovery, which is do we actually know of a certain drug, a small molecule, a biologic, a peptide, a cell-based therapy? Do we do we know what that is and what it targets and how it's producing an effect? That's the first thing. That's discovery. Then we have development, which is have we tested that drug over a long period of time? in humans for safety and efficacy? What we're gonna see with AI is discovery gets solved. I feel very comfortable with the statement of the next five years, we're gonna have millions of drugs discovered by AI. And I

47:03Unidentified speaker (UNKNOWN): think

47:03Unidentified speaker (speaker_1): that Eli will do that, and I think Anthropic will do that. And they'll probably be the two primary drug discovery companies in the world. That's my prediction. Now, this sounds great. but we still have a clinical bottleneck, right? We still have to test those drugs. And the current paradigm of testing those drugs is putting them in humans over long periods of time and observing the results. Well, good luck putting millions of new drugs in humans over long periods of time. That sounds quite complex. So I think we need some sort of way of solving the clinical part of the discovery and development process. I think that there are multiple plausible ways that happens. Um, the the there's there's like one argument that we'll enter a libertarian state where you prove safety and then we let a free market determine efficacy. Right to try is maybe the first example of that. I think that's actually quite low probability. I think a second thing is we um just as we do computational discovery, right? We use AI to discover, we also do computational development. So we actually have. simulations of of the human or the cell or the organ that um the FDA has deemed a suitable to replace the actual testing in a human. I think that will eventually happen, but it's a little bit far off. And then we have maybe some i intermediate solutions. Do we have little organoids that we can test on, right? We grow little organs and chips and we test on them. Do

48:23they're in space so things can happen a little bit faster. I think those things are quite likely. So um discover will be solved pretty quickly, likely primarily by Eli and Anthropic. And then um uh actual kind of development and trials will be solved a little bit later, but AI will solve that as well.

48:38Jonathan Stern: Your sense is that anthropic is ahead of OpenAI here?

48:42Unidentified speaker (speaker_1): I think so.

48:43Unidentified speaker (UNKNOWN): Okay.

48:44Unidentified speaker (speaker_1): Valrio has just been more obsessed about the problem for longer. He was a biologist um by by kind of training. Um So I think so.

48:52Jonathan Stern: Dario said earlier in the week cancer, Alzheimer's, heart disease, and mental illness will be relics of the past within 10 years. Do you agree?

49:02Unidentified speaker (speaker_1): Uh yes.

49:05Jonathan Stern: Andrew Dudham said he agreed 100%.

49:09Unidentified speaker (speaker_1): Mm-hmm.

49:10Jonathan Stern: Eli Lilly's CEO diverged.

49:14Unidentified speaker (UNKNOWN): He said

49:14Jonathan Stern: he can't. quite agree.

49:16Unidentified speaker (speaker_1): Oh, really? Okay. Yeah. Um, I think that um uh it depends on how quick development can move, right? I do think we will discover solutions to these things. It just depends on whether we can develop computational models of biology that can replace clinical trials, or we can have some sort of kind of organoid or humanoid. even to go to the extreme that allows us to test efficacy and safety in humans or human-like tissue.

49:46Jonathan Stern: He said he thinks progress will be steady and incremental. It sounds like you think progress will be exponential, just limited by what we're actually able to do in the real world.

49:57Unidentified speaker (speaker_1): Mm-hmm. Yeah.

49:58Unidentified speaker (UNKNOWN): Is that

49:58Jonathan Stern: right?

49:59Unidentified speaker (UNKNOWN): Is

49:59Jonathan Stern: that right? Okay. Max, Marchioni. thank you so much for being a part of him's house.

50:06Unidentified speaker (speaker_1): Pleasure. Jonathan, always fun to chat.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights